377 related articles for article (PubMed ID: 23813697)
61. Effects of Curcumin Combined With the 5-alpha Reductase Inhibitor Dutasteride on LNCaP Prostate Cancer Cells.
Nakayama A; Ide H; Lu Y; Takei A; Fukuda K; Osaka A; Arai G; Horie S; Okada H; Saito K
In Vivo; 2021; 35(3):1443-1450. PubMed ID: 33910821
[TBL] [Abstract][Full Text] [Related]
62. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men.
Amory JK; Anawalt BD; Matsumoto AM; Page ST; Bremner WJ; Wang C; Swerdloff RS; Clark RV
J Urol; 2008 Jun; 179(6):2333-8. PubMed ID: 18423697
[TBL] [Abstract][Full Text] [Related]
63. Dihydrotestosterone synthesis from adrenal precursors does not involve testosterone in castration-resistant prostate cancer.
Campbell TJ; Tindall DJ; Figg WD
Cancer Biol Ther; 2012 Mar; 13(5):237-8. PubMed ID: 22336886
[TBL] [Abstract][Full Text] [Related]
64. Cynanchum wilfordii Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Regulating 5α-Reductase and Androgen Receptor Activities in a Rat Model.
Lee G; Shin J; Choi H; Jo A; Pan S; Bae D; Lee Y; Choi C
Nutrients; 2017 Sep; 9(10):. PubMed ID: 28953224
[TBL] [Abstract][Full Text] [Related]
65. Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.
Traish AM
Adv Exp Med Biol; 2017; 1043():473-526. PubMed ID: 29224108
[TBL] [Abstract][Full Text] [Related]
66. Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogenital tract.
George FW
Endocrinology; 1997 Mar; 138(3):871-7. PubMed ID: 9048585
[TBL] [Abstract][Full Text] [Related]
67. Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues.
Bauman TM; Sehgal PD; Johnson KA; Pier T; Bruskewitz RC; Ricke WA; Huang W
Prostate; 2014 Jun; 74(9):923-32. PubMed ID: 24789081
[TBL] [Abstract][Full Text] [Related]
68. Development of a new gas chromatography-mass spectrometry (GC-MS) methodology for the evaluation of 5α-reductase activity.
Amaral C; Cunha SC; Fernandes JO; Tavares da Silva E; Roleira FM; Teixeira N; Correia-da-Silva G
Talanta; 2013 Mar; 107():154-61. PubMed ID: 23598206
[TBL] [Abstract][Full Text] [Related]
69. Human osteoblast-like cells express predominantly steroid 5alpha-reductase type 1.
Issa S; Schnabel D; Feix M; Wolf L; Schaefer HE; Russell DW; Schweikert HU
J Clin Endocrinol Metab; 2002 Dec; 87(12):5401-7. PubMed ID: 12466325
[TBL] [Abstract][Full Text] [Related]
70. In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5alpha-reductase inhibitors.
Bratoeff E; Cabeza M; Pérez-Ornelas V; Recillas S; Heuze I
J Steroid Biochem Mol Biol; 2008 Sep; 111(3-5):275-81. PubMed ID: 18644453
[TBL] [Abstract][Full Text] [Related]
71. Prostatic involution in rats induced by a novel 5 alpha-reductase inhibitor, SK&F 105657: role for testosterone in the androgenic response.
Lamb JC; English H; Levandoski PL; Rhodes GR; Johnson RK; Isaacs JT
Endocrinology; 1992 Feb; 130(2):685-94. PubMed ID: 1733716
[TBL] [Abstract][Full Text] [Related]
72. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
Festuccia C; Gravina GL; Muzi P; Pomante R; Angelucci A; Vicentini C; Bologna M
J Urol; 2008 Jul; 180(1):367-72. PubMed ID: 18499161
[TBL] [Abstract][Full Text] [Related]
73. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.
Page ST; Hirano L; Gilchriest J; Dighe M; Amory JK; Marck BT; Matsumoto AM
J Urol; 2011 Jul; 186(1):191-7. PubMed ID: 21575967
[TBL] [Abstract][Full Text] [Related]
74. Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer.
Nnane IP; Kato K; Liu Y; Lu Q; Wang X; Ling YZ; Brodie A
Cancer Res; 1998 Sep; 58(17):3826-32. PubMed ID: 9731491
[TBL] [Abstract][Full Text] [Related]
75. Transcriptomic profiling in Silurana tropicalis testes exposed to finasteride.
Bissegger S; Martyniuk CJ; Langlois VS
Gen Comp Endocrinol; 2014 Jul; 203():137-45. PubMed ID: 24530632
[TBL] [Abstract][Full Text] [Related]
76. Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression.
Habib FK; Ross M; Ho CK; Lyons V; Chapman K
Int J Cancer; 2005 Mar; 114(2):190-4. PubMed ID: 15543614
[TBL] [Abstract][Full Text] [Related]
77. Comparative study of human steroid 5alpha-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride.
Ranjan M; Diffley P; Stephen G; Price D; Walton TJ; Newton RP
Life Sci; 2002 May; 71(2):115-26. PubMed ID: 12031682
[TBL] [Abstract][Full Text] [Related]
78. Comparison of the effects of new specific azasteroid inhibitors of steroid 5 alpha-reductase on canine hyperplastic prostate: suppression of prostatic DHT correlated with prostate regression.
Cohen SM; Werrmann JG; Rasmusson GH; Tanaka WK; Malatesta PF; Prahalada S; Jacobs JG; Harris G; Nett TM
Prostate; 1995 Feb; 26(2):55-71. PubMed ID: 7531846
[TBL] [Abstract][Full Text] [Related]
79. The Postnatal Offspring of Finasteride-Treated Male Rats Shows Hyperglycaemia, Elevated Hepatic Glycogen Storage and Altered GLUT2, IR, and AR Expression in the Liver.
Kur P; Kolasa-Wołosiuk A; Grabowska M; Kram A; Tarnowski M; Baranowska-Bosiacka I; Rzeszotek S; Piasecka M; Wiszniewska B
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513940
[TBL] [Abstract][Full Text] [Related]
80. CGP 53153: a new potent inhibitor of 5alpha-reductase.
Häusler A; Allegrini PR; Biollaz M; Batzl C; Scheidegger E; Bhatnagar AS
J Steroid Biochem Mol Biol; 1996 Feb; 57(3-4):187-95. PubMed ID: 8645628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
